• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弓形虫病的治疗:当前选择与未来展望

Treatment of toxoplasmosis: Current options and future perspectives.

作者信息

Konstantinovic Neda, Guegan Hélène, Stäjner Tijana, Belaz Sorya, Robert-Gangneux Florence

机构信息

National Reference Laboratory for Toxoplasmosis, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset - UMR_S 1085, F-35000 Rennes, France.

出版信息

Food Waterborne Parasitol. 2019 Apr 1;15:e00036. doi: 10.1016/j.fawpar.2019.e00036. eCollection 2019 Jun.

DOI:10.1016/j.fawpar.2019.e00036
PMID:32095610
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7033996/
Abstract

Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with possible severe outcomes in neonates and immunocompromised patients. Despite continuous and successful efforts to improve diagnosis, therapeutic schemes have barely evolved since many years. This article aims at reviewing the main clinical trials and current treatment practices, and at addressing future perspectives in the light of ongoing researches.

摘要

弓形虫病是一种全球性的寄生虫病,感染了约三分之一的人类,在新生儿和免疫功能低下的患者中可能会导致严重后果。尽管在改进诊断方面持续做出了成功努力,但多年来治疗方案几乎没有进展。本文旨在综述主要的临床试验和当前的治疗实践,并根据正在进行的研究探讨未来的前景。

相似文献

1
Treatment of toxoplasmosis: Current options and future perspectives.弓形虫病的治疗:当前选择与未来展望
Food Waterborne Parasitol. 2019 Apr 1;15:e00036. doi: 10.1016/j.fawpar.2019.e00036. eCollection 2019 Jun.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Toxoplasmosis: Overview from a One Health perspective.弓形虫病:“同一健康”视角下的概述
Food Waterborne Parasitol. 2019 Apr 18;15:e00054. doi: 10.1016/j.fawpar.2019.e00054. eCollection 2019 Jun.
5
[Current options for the diagnosis and therapy of toxoplasmosis in HIV-negative patients].[HIV 阴性患者弓形虫病的当前诊断与治疗选择]
Klin Mikrobiol Infekc Lek. 2009 Jun;15(3):83-90.
6
A Review on the Present Advances on Studies of Toxoplasmosis in Eastern Africa.东非弓形虫病研究进展述评。
Biomed Res Int. 2020 Jul 6;2020:7135268. doi: 10.1155/2020/7135268. eCollection 2020.
7
The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis.阿奇霉素在弓形虫病预防治疗中的潜在作用。
Int J STD AIDS. 1996;7 Suppl 1:18-22. doi: 10.1258/0956462961917267.
8
Molecular diagnosis of toxoplasmosis: recent advances and a look to the future.弓形虫病的分子诊断:最新进展与未来展望
Expert Rev Anti Infect Ther. 2021 Dec;19(12):1529-1542. doi: 10.1080/14787210.2021.1941867. Epub 2021 Aug 21.
9
[Genotyping of Toxoplasma gondii strains from immunocompromised patients].[免疫功能低下患者弓形虫菌株的基因分型]
Pathol Biol (Paris). 2000 Jul;48(6):541-7.
10
General Features and Laboratory Diagnosis of Infection.感染的一般特征与实验室诊断
Turkiye Parazitol Derg. 2020 Jun 2;44(2):94-101. doi: 10.4274/tpd.galenos.2020.6634.

引用本文的文献

1
In Vivo Safety and Efficacy of Thiosemicarbazones in Experimental Mice Infected with Oocysts.硫代氨基脲类化合物在感染卵囊的实验小鼠体内的安全性和有效性
Biomedicines. 2025 Aug 1;13(8):1879. doi: 10.3390/biomedicines13081879.
2
Toxoplasma gondii-induced host's high secretion of 25-hydroxycholesterol for immunoprotection.弓形虫诱导宿主大量分泌25-羟基胆固醇以进行免疫保护。
Parasit Vectors. 2025 Aug 4;18(1):333. doi: 10.1186/s13071-025-06890-0.
3
Phenotypic Screening of the MMV Global Health Priority Box Identifies Selective Compounds with Anti- Activity.MMV全球健康优先药物库的表型筛选鉴定出具有抗活性的选择性化合物。
ACS Omega. 2025 Jul 10;10(28):31147-31152. doi: 10.1021/acsomega.5c05130. eCollection 2025 Jul 22.
4
Antileishmanial and Antitoxoplasmal Activities of 1,4-Dihydropyridines.1,4 - 二氢吡啶的抗利什曼原虫和抗弓形虫活性
ACS Omega. 2025 Jul 10;10(28):31066-31076. doi: 10.1021/acsomega.5c04551. eCollection 2025 Jul 22.
5
Comparative evaluation of live attenuated and killed tachyzoites as vaccine candidates for toxoplasmosis.减毒活速殖子与灭活速殖子作为弓形虫病候选疫苗的比较评价
AMB Express. 2025 Jul 10;15(1):102. doi: 10.1186/s13568-025-01889-3.
6
Lack of knowledge of stakeholders in the pork value chain: Considerations for transmission and control of Taenia solium and Toxoplasma gondii in Burundi.猪肉价值链中利益相关者的知识欠缺:布隆迪猪带绦虫和刚地弓形虫传播与控制的考量因素
PLoS One. 2025 Jul 2;20(7):e0326238. doi: 10.1371/journal.pone.0326238. eCollection 2025.
7
Propolis Stands out as a Multifaceted Natural Product: Meta-Analysis on Its Sources, Bioactivities, Applications, and Future Perspectives.蜂胶作为一种多面性的天然产物脱颖而出:对其来源、生物活性、应用及未来展望的荟萃分析。
Life (Basel). 2025 May 9;15(5):764. doi: 10.3390/life15050764.
8
Phytochemical content of Cycas rumphii n-butanol fraction and antiprotozoal activity against Toxoplasma gondii in vivo.苏铁正丁醇部位的植物化学成分及其对刚地弓形虫的体内抗寄生虫活性。
Sci Rep. 2025 May 5;15(1):15697. doi: 10.1038/s41598-025-98993-y.
9
Treatment Protocols for Gestational and Congenital Toxoplasmosis: A Systematic Review and Meta-Analysis.妊娠期和先天性弓形虫病的治疗方案:系统评价与荟萃分析
Microorganisms. 2025 Mar 24;13(4):723. doi: 10.3390/microorganisms13040723.
10
N-(9-Acridinyl) Amino Acid Derivatives: Synthesis and In Vitro Evaluation of Anti- Activity.N-(9-吖啶基)氨基酸衍生物:抗活性的合成与体外评价
Pharmaceutics. 2025 Mar 15;17(3):374. doi: 10.3390/pharmaceutics17030374.

本文引用的文献

1
A one health approach to vaccines against .一种针对……的疫苗的一体化健康方法。 (原文表述不完整,翻译可能不太准确,建议提供完整原文)
Food Waterborne Parasitol. 2019 Apr 18;15:e00053. doi: 10.1016/j.fawpar.2019.e00053. eCollection 2019 Jun.
2
A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization.弓形虫抗原的系统评价,以寻找最佳的疫苗候选物进行免疫。
Microb Pathog. 2019 Jan;126:172-184. doi: 10.1016/j.micpath.2018.11.003. Epub 2018 Nov 3.
3
CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in .CSGID 解决了. 中五种酶的结构和表型鉴定问题。
Front Cell Infect Microbiol. 2018 Oct 5;8:352. doi: 10.3389/fcimb.2018.00352. eCollection 2018.
4
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.弓形虫病的治疗:历史视角、动物模型和当前临床实践。
Clin Microbiol Rev. 2018 Sep 12;31(4). doi: 10.1128/CMR.00057-17. Print 2018 Oct.
5
The immunomodulatory effects of rolipram abolish drug-resistant latent phase of infection in a murine model.咯利普兰的免疫调节作用消除了小鼠模型中耐药性感染的潜伏期。
J Microsc Ultrastruct. 2015 Apr-Jun;3(2):86-91. doi: 10.1016/j.jmau.2014.12.001. Epub 2015 Jan 7.
6
Toxoplasmosis in Transplant Recipients, Europe, 2010-2014.欧洲 2010-2014 年器官移植受者弓形虫病感染情况。
Emerg Infect Dis. 2018 Aug;24(8):1497-1504. doi: 10.3201/eid2408.180045.
7
Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.评估现有及新型抗疟药物对体外培养的刚地弓形虫生长的抑制作用
ACS Infect Dis. 2018 Aug 10;4(8):1264-1274. doi: 10.1021/acsinfecdis.8b00113. Epub 2018 Jul 25.
8
Toxoplasmosis in the non-orthotopic heart transplant recipient population, how common is it? Any indication for prophylaxis?在非原位心脏移植受者群体中,弓形虫病有多常见?有预防的指征吗?
Curr Opin Organ Transplant. 2018 Aug;23(4):407-416. doi: 10.1097/MOT.0000000000000550.
9
Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial.用氨苯砜+磺胺嘧啶与螺旋霉素进行产前治疗以减少弓形虫病的胎盘传播:一项多中心、随机试验。
Am J Obstet Gynecol. 2018 Oct;219(4):386.e1-386.e9. doi: 10.1016/j.ajog.2018.05.031. Epub 2018 Jun 2.
10
Metallopeptidases of Toxoplasma gondii: in silico identification and gene expression.刚地弓形虫金属肽酶:计算机鉴定与基因表达
Parasite. 2018;25:26. doi: 10.1051/parasite/2018025. Epub 2018 May 8.